We are making biology programmable to transform health and sustainability for the benefit of all. We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering. Contact us to work with us today.
Latent Labs的外部链接
"If you can compress the timelines, if you can reduce risk, if you open up new areas in biologics, then that's a huge opportunity." Our CEO, Simon Kohl, on Bloomberg Television with Tom Mackenzie.
"We are working on making biology programable." Latent Labs CEO Simon Kohl tells Tom Mackenzie how his firm uses artificial intelligence to reduce risk and speed up timelines in drug discovery.?https://trib.al/4Sdn57y
Simon Kohl, CEO and Founder of Latent Labs, appeared on Bloomberg News Daybreak Europe this morning to discuss our $50M Series A funding round and our approach to making biology programmable. As Simon articulated, "We're building frontier AI models that learn the fundamentals of biochemistry, and we will be able to apply these successfully to antibody design, protein engineering, such as enzyme optimization, built tooling for genetic engineering, and we do believe that there is a significant opportunity to move the drug discovery process into the computational realm. That is our North Star." You can watch the full interview starting from 37:05 at the link below: https://lnkd.in/eEQDNU_z Thank you to the team at Bloomberg Daybreak?Europe and Tom Mackenzie?for the conversation.
This morning, I had the privilege of discussing Latent Labs' recent $50M funding and our mission to make biology programmable on Bloomberg News Daybreak Europe. Our goal at Latent Labs is to build frontier AI models that learn the fundamentals of biochemistry. Thank you to Tom Mackenzie and the Bloomberg Daybreak team for the conversation. For those interested, you can watch the full interview starting at 37:05 via the link below: https://lnkd.in/edCauK_q
"Latent Labs?is building AI foundation models to “make biology programmable”, and it plans to partner with biotech and pharmaceutical companies to generate and optimize proteins." Huge thanks to TechCrunch, our investors & supporters - this is just the beginning. Follow us as we push the frontiers of AI & biology. https://lnkd.in/gYj3pHwc
"What if scientists could create the building blocks of new medicines completely from scratch, targeting diseases with precisely designed cures? That is the vision of?Latent Labs, a London- and San Francisco-based start-up, which is today announcing it has now raised $50 million of new funding." Thank you Forbes and David Prosser for the coverage: https://lnkd.in/e8pCf52P
"One of DeepMind’s Nobel-prize winning AlphaFold team has raised $50 million to launch his own venture designing new proteins, with the goal of “achieving computational mastery over biology”." Thank you The Times and?@richardtyler for featuring us:?https://lnkd.in/eh6YapRm This is just the beginning of our journey. Follow us as we scale our team, forge partnerships and advance our platform.
"Simon Kohl, a scientist who helped build DeepMind’s protein prediction programme, which won the company’s co-founder a Nobel Prize, has raised $50mn to launch a startup to discover new drugs." We’re grateful for the incredible response to our mission. A huge thank you to Financial Times?and Hannah Kuchler and Melissa Heikkil? for the coverage, as well as our investors, partners and supporters - this is just the beginning. https://lnkd.in/eF25ZPN2
We are out of stealth with $50M in funding. Join us on our moonshot mission of making biology programmable and reach out to work with us today.
Latent Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design. Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can?play - but not all are in a position to develop their own advanced models. That’s where Latent Labs comes in. The funding includes our Series A co-led by Radical Ventures and Sofinnova Partners, with existing investors Pillar VC, Kindred Capital VC and 8VC participating alongside new investors Isomer Capital and Flying Fish Partners. Our angel investors include Google Chief Scientist Jeff Dean, Transformer architecture co-inventor and Cohere founder Aidan Gomez, and ElevenLabs founder Mati Staniszewski. I loved my time at DeepMind working on AlphaFold2 and to be there in Stockholm to watch Demis Hassabis and John Jumper accept the Nobel Prize was incredible. It is clear protein design has the potential to transform medicine and scientific discovery. I believe Latent Labs will be the team to fully realize its potential. It’s a vast field and there’s so much still to do. Let’s go! Apply to access our tools or join the team www.latentlabs.com.